Fig 5. Combination of olaparib and CHK1i restores sensitivity to EMI1-depleted MDA-MB-436 and SUM149PT cells.
(A) MDA-MB-436 cells were transfected with control siRNA or EMI1-specific siRNA1 and grown for 96 h in medium containing vehicle plus olaparib at the indicated concentrations (solid lines) or in medium containing 10 μM CHK1i plus olaparib at the indicated concentrations (dashed lines). Proliferation assays (n = 3) measured the growth of the cells under each condition. The growth of control siRNA transfected cells was compared to the growth of EMI1 depleted cultures grown in the absence of CHK1i and in the presence of CHK1i. P-values comparing the growth of EMI1-depleted cells versus control siRNA-transfected cells were less than 0.05 at olaparib concentrations of 2.5 μM and 10 μM in the presence of a single drug, but in the presence of both drugs, the p-values were not significant. Protein lysates from one replicate were analyzed by immunoblot for EMI1 and RAD51 protein abundance (right). (B) SUM149PT cells were transfected with control siRNA or EMI1-specific siRNA1 or siRNA2 and grown for 96 h in medium containing vehicle plus olaparib at the indicated concentrations (solid lines) or in medium containing 0.1μM CHK1i plus olaparaib at the indicated concentrations (dashed lines) and analyzed as in panel A. When comparing EMI1-siRNA1 to control siRNA, p-values were less than 0.05 at concentrations of olaparib of 0.125 μM, 1.25 μM, 2.5 μM, and 5 μM when testing the single drug, and was not significant (p > 0.05) at all concentrations when comparing EMI1 siRNA1 to control siRNA in two drugs. When comparing EMI1-siRNA2 to control siRNA, p-values were less than 0.05 at all concentrations of olaparib tested in the single drug and in the two drug conditions. (C) CompuSyn software analysis of additive effects of olaparib and CHK1i in MDA-MB-436 cells. The dose effect (x-axis) was plotted against the fraction of the total drug effect (Fa, y-axis) for olaparib alone (blue ovals), CHK1i alone (red rectangles) or the combination of both drugs (green triangles) in control siRNA transfected cells (left) and EMI1 siRNA1 depleted cells (right).